UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Promising curcumin-based drug design: mono-carbonyl analogues of curcumin (MACs)

Current pharmaceutical design, 2013-04, Vol.19 (11), p.2114

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours

British journal of cancer, 2019-02, Vol.120 (4), p.379-386

2019

Link zum Volltext

Verfügbarkeit prüfen

A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma

Neurosurgery, 2021-02, Vol.88 (2), p.246-251

2021

Link zum Volltext

Verfügbarkeit prüfen

Sustained Accumulation of Microtubule-Binding Chemotherapy Drugs in the Peripheral Nervous System: Correlations with Time Course and Neurotoxic Severity

Cancer research (Chicago, Ill.), 2016-06, Vol.76 (11), p.3332-3339

2016

Link zum Volltext

Verfügbarkeit prüfen

Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics for In vivo Efficacy under Intermittent Dosing Conditions

Cancer research (Chicago, Ill.), 2011-01, Vol.71 (2), p.496-505

2011

Link zum Volltext

Verfügbarkeit prüfen

Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach

Cancer chemotherapy and pharmacology, 2022-02, Vol.89 (2), p.197-208

2022

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of BBB permeable nucleolipid (NLDPU): A di-C15-ketalised palmitone appended uridine as neuro-tracer for SPECT

International journal of pharmaceutics, 2019-06, Vol.565, p.269-282

2019

Link zum Volltext

Verfügbarkeit prüfen

Eribulin Mesylate

Clinical cancer research, 2011-11, Vol.17 (21), p.6615-6622

2011

Link zum Volltext

Verfügbarkeit prüfen

A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine

British journal of cancer, 2019-03, Vol.120 (6), p.579-586

2019

Link zum Volltext

Verfügbarkeit prüfen

Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin

Science translational medicine, 2014-11, Vol.6 (261), p.261ra152

2014

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial

Cancer chemotherapy and pharmacology, 2015-11, Vol.76 (5), p.897-907

2015

Link zum Volltext

Verfügbarkeit prüfen

Effects of Eribulin on Microtubule Binding and Dynamic Instability Are Strengthened in the Absence of the βIII Tubulin Isotype

Biochemistry (Easton), 2015-10, Vol.54 (42), p.6482-6489

2015

Link zum Volltext

Verfügbarkeit prüfen

Eribulin in Cancer Treatment

Marine Drugs, 2015-08, Vol.13 (8), p.5016-5058

2015

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetic–pharmacodynamic analysis for eribulin mesilate‐associated neutropenia

British journal of clinical pharmacology, 2013-09, Vol.76 (3), p.412-424

2013

Link zum Volltext

Verfügbarkeit prüfen

Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for Chagas’ disease

Bioorganic & medicinal chemistry letters, 2015-11, Vol.25 (21), p.4834-4837

2015

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic and metabolic profiling studies of osmundacetone in rats by UPLC–MS/MS and UPLC–QE–Orbitrap–HRMS

Biomedical chromatography, 2022-01, Vol.36 (1), p.e5251-n/a

2022

Link zum Volltext

Verfügbarkeit prüfen

Tuning Reactivity of Diphenylpropynone Derivatives with Metal-Associated Amyloid‑β Species via Structural Modifications

Inorganic chemistry, 2013-07, Vol.52 (14), p.8121-8130

2013

Link zum Volltext

Verfügbarkeit prüfen

A Peptide-Based Positron Emission Tomography Probe for In Vivo Detection of Caspase Activity in Apoptotic Cells

Clinical cancer research, 2014-04, Vol.20 (8), p.2126-2135

2014

Link zum Volltext

Verfügbarkeit prüfen

Urinary excretion of heptanones, heptanoles and 2,5-heptanedione after controlled acute exposure of volunteers to n-heptane

Toxicology letters, 2018-12, Vol.298, p.81-90

2018

Link zum Volltext

Verfügbarkeit prüfen

Insights from zebrafish and mouse models on the activity and safety of ar-turmerone as a potential drug candidate for the treatment of epilepsy

PloS one, 2013-12, Vol.8 (12), p.e81634

2013

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of Thrombin With PPACK-Nanoparticles Restores Disrupted Endothelial Barriers and Attenuates Thrombotic Risk in Experimental Atherosclerosis

Arteriosclerosis, thrombosis, and vascular biology, 2016-03, Vol.36 (3), p.446

2016

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function

Cancer chemotherapy and pharmacology, 2015-11, Vol.76 (5), p.1051-1061

2015

Link zum Volltext

Verfügbarkeit prüfen

Eribulin mesylate in patients with refractory cancers: a Phase I study

Investigational new drugs, 2012-10, Vol.30 (5), p.1926-1933

2012

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of Paradol Analogues Orally Administered to Rats

Journal of agricultural and food chemistry, 2016-03, Vol.64 (9), p.1932-1937

2016

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamic analysis of eribulin safety in breast cancer patients using real‐world postmarketing surveillance data

Cancer science, 2018-09, Vol.109 (9), p.2822-2829

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 410

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(385)
Mit Volltextzugriff
(363)

Publikationsform

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Promising curcumin-based drug design: mono-carbonyl analogues of curcumin (MACs)

Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours

A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma

Sustained Accumulation of Microtubule-Binding Chemotherapy Drugs in the Peripheral Nervous System: Correlations with Time Course and Neurotoxic Severity

Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics for In vivo Efficacy under Intermittent Dosing Conditions

Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach

Evaluation of BBB permeable nucleolipid (NLDPU): A di-C15-ketalised palmitone appended uridine as neuro-tracer for SPECT

Eribulin Mesylate

A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine

Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin

Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial

Effects of Eribulin on Microtubule Binding and Dynamic Instability Are Strengthened in the Absence of the βIII Tubulin Isotype

Eribulin in Cancer Treatment

Population pharmacokinetic–pharmacodynamic analysis for eribulin mesilate‐associated neutropenia

Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for Chagas’ disease

Pharmacokinetic and metabolic profiling studies of osmundacetone in rats by UPLC–MS/MS and UPLC–QE–Orbitrap–HRMS

Tuning Reactivity of Diphenylpropynone Derivatives with Metal-Associated Amyloid‑β Species via Structural Modifications

A Peptide-Based Positron Emission Tomography Probe for In Vivo Detection of Caspase Activity in Apoptotic Cells

Urinary excretion of heptanones, heptanoles and 2,5-heptanedione after controlled acute exposure of volunteers to n-heptane

Insights from zebrafish and mouse models on the activity and safety of ar-turmerone as a potential drug candidate for the treatment of epilepsy

Inhibition of Thrombin With PPACK-Nanoparticles Restores Disrupted Endothelial Barriers and Attenuates Thrombotic Risk in Experimental Atherosclerosis

Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function

Eribulin mesylate in patients with refractory cancers: a Phase I study

Pharmacokinetics of Paradol Analogues Orally Administered to Rats

Pharmacodynamic analysis of eribulin safety in breast cancer patients using real‐world postmarketing surveillance data

Suchergebnisse filtern